Capricor Therapeutics, Inc. (CAPR): Operating Income
-$108.14M
Year ended 2025-12-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$108.14M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$42.56M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$24.08M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | -$29.70M | n/m | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | -$20.94M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$13.69M | n/m | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | -$7.73M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$15.33M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$12.86M | n/m | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | -$16.98M | n/m | 2018-03-22, From 2016-01-01 |
| 2015-12-31 | -$12.61M | n/m | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | -$6.02M | n/m | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | -$6.90M | n/m | 2015-03-16, From 2013-01-01 |
| 2012-12-31 | -$2.10M | n/c | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | -$4.90M | n/m | 2013-06-21, From 2011-01-01 |
| 2010-12-31 | -$6.29M | n/a | 2012-04-02, From 2010-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | -$108.14M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare CAPR, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗